HI
ALNY icon

Horizon Investments’s Alnylam Pharmaceuticals ALNY Stock Holding History

Horizon Investments’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$499K Sell
1,656
-976
-37% -$294K 0.01% 873
2026
Q1 		$871K Buy
2,632
+2,181
+484% +$742K 0.01% 694
2025
Q4 		$179K Buy
451
+48
+12% +$21.2K ﹤0.01% 975
2025
Q3 		$184K Buy
403
+63
+19% +$25.7K ﹤0.01% 926
2025
Q2 		$111K Buy
+340
New +$94.1K ﹤0.01% 942

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Horizon Investments's ALNY Position: Q2 2026 in Review

Horizon Investments reduced its Alnylam Pharmaceuticals (ALNY) stake by 37% in Q2 2026, selling an estimated $294K and leaving 1,656 shares worth $499K. The position accounts for 0.01% of the portfolio, ranked #873.

Horizon Investments first reported a position in ALNY in Q2 2025 and has held it in 5 quarters since. The position peaked at $871K in Q1 2026. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Horizon Investments held 1,656 shares of Alnylam Pharmaceuticals worth $499K as of Q2 2026.
  • Horizon Investments sold 976 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $294K.
  • Alnylam Pharmaceuticals made up 0.01% of Horizon Investments's portfolio in Q2 2026, its #873 holding.
  • Horizon Investments first reported a position in Alnylam Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Horizon Investments's Alnylam Pharmaceuticals position peaked at $871K in Q1 2026.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Horizon Investments's 13F filing for Q2 2026, filed 13 Aug 2026.